Rifampicin combined regimens for Gram-negative infections: data from the literature

C. M J Drapeau, E. Grilli, N. Petrosillo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Multidrug-resistant (MDR) Gram-negative bacterial infections are associated with high morbidity and mortality. Given the lack of availability of new highly effective antimicrobial drugs against multiresistant strains, combination regimens are administered that include rifampicin for its demonstrated in vitro synergism with multiple drugs. A literature review was performed of clinical studies reporting the use of rifampicin in the treatment of MDR Gram-negative bacterial infections. Nineteen studies were found, including only one randomised controlled study. Data in the literature on combined therapeutic regimens with rifampicin are limited and refer mostly to uncontrolled studies. Therefore, the real clinical benefit of using rifampicin-containing therapies for the treatment of Gram-negative multiresistant bacteria in terms of clinical outcome and survival rates still needs to be assessed.

Original languageEnglish
Pages (from-to)39-44
Number of pages6
JournalInternational Journal of Antimicrobial Agents
Volume35
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Rifampin
Gram-Negative Bacterial Infections
Infection
Gram-Negative Bacteria
Pharmaceutical Preparations
Survival Rate
Morbidity
Mortality
Therapeutics

Keywords

  • Combination regimens
  • Gram-negative
  • Rifampicin
  • Synergism

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Pharmacology (medical)

Cite this

Rifampicin combined regimens for Gram-negative infections : data from the literature. / Drapeau, C. M J; Grilli, E.; Petrosillo, N.

In: International Journal of Antimicrobial Agents, Vol. 35, No. 1, 01.2010, p. 39-44.

Research output: Contribution to journalArticle

@article{17fe56d7556b4a1482ea234fff7ef7ac,
title = "Rifampicin combined regimens for Gram-negative infections: data from the literature",
abstract = "Multidrug-resistant (MDR) Gram-negative bacterial infections are associated with high morbidity and mortality. Given the lack of availability of new highly effective antimicrobial drugs against multiresistant strains, combination regimens are administered that include rifampicin for its demonstrated in vitro synergism with multiple drugs. A literature review was performed of clinical studies reporting the use of rifampicin in the treatment of MDR Gram-negative bacterial infections. Nineteen studies were found, including only one randomised controlled study. Data in the literature on combined therapeutic regimens with rifampicin are limited and refer mostly to uncontrolled studies. Therefore, the real clinical benefit of using rifampicin-containing therapies for the treatment of Gram-negative multiresistant bacteria in terms of clinical outcome and survival rates still needs to be assessed.",
keywords = "Combination regimens, Gram-negative, Rifampicin, Synergism",
author = "Drapeau, {C. M J} and E. Grilli and N. Petrosillo",
year = "2010",
month = "1",
doi = "10.1016/j.ijantimicag.2009.08.011",
language = "English",
volume = "35",
pages = "39--44",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Rifampicin combined regimens for Gram-negative infections

T2 - data from the literature

AU - Drapeau, C. M J

AU - Grilli, E.

AU - Petrosillo, N.

PY - 2010/1

Y1 - 2010/1

N2 - Multidrug-resistant (MDR) Gram-negative bacterial infections are associated with high morbidity and mortality. Given the lack of availability of new highly effective antimicrobial drugs against multiresistant strains, combination regimens are administered that include rifampicin for its demonstrated in vitro synergism with multiple drugs. A literature review was performed of clinical studies reporting the use of rifampicin in the treatment of MDR Gram-negative bacterial infections. Nineteen studies were found, including only one randomised controlled study. Data in the literature on combined therapeutic regimens with rifampicin are limited and refer mostly to uncontrolled studies. Therefore, the real clinical benefit of using rifampicin-containing therapies for the treatment of Gram-negative multiresistant bacteria in terms of clinical outcome and survival rates still needs to be assessed.

AB - Multidrug-resistant (MDR) Gram-negative bacterial infections are associated with high morbidity and mortality. Given the lack of availability of new highly effective antimicrobial drugs against multiresistant strains, combination regimens are administered that include rifampicin for its demonstrated in vitro synergism with multiple drugs. A literature review was performed of clinical studies reporting the use of rifampicin in the treatment of MDR Gram-negative bacterial infections. Nineteen studies were found, including only one randomised controlled study. Data in the literature on combined therapeutic regimens with rifampicin are limited and refer mostly to uncontrolled studies. Therefore, the real clinical benefit of using rifampicin-containing therapies for the treatment of Gram-negative multiresistant bacteria in terms of clinical outcome and survival rates still needs to be assessed.

KW - Combination regimens

KW - Gram-negative

KW - Rifampicin

KW - Synergism

UR - http://www.scopus.com/inward/record.url?scp=70849121220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70849121220&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2009.08.011

DO - 10.1016/j.ijantimicag.2009.08.011

M3 - Article

C2 - 19815392

AN - SCOPUS:70849121220

VL - 35

SP - 39

EP - 44

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 1

ER -